| T14011 |
2-Arachidonoylglycerol
|
53847-30-6
|
98%
|
|
|
In the central nervous system, 2-Arachidonoylglycerol is a second endogenous cannabinoid ligand
|
| T64394 |
GW 833972A
|
1092502-33-4
|
98%
|
|
|
GW 833972A is a selective CB2 receptor agonist.GW 833972A has an inhibitory effect on induced neural depolarization and on citric acid-induced cough in an animal...
|
| T79909 |
AEF0117
|
1610878-71-1
|
98%
|
|
|
AEF0117, a signaling-specific inhibitor of cannabinoid receptor 1 (CB1-SSi), inhibits cannabinoid self-administration and behavioral disorders associated with TH...
|
| T19705 |
JTE-907
|
282089-49-0
|
100%
|
|
|
JTE-907 is a CB2 receptor inverse agonist with high selectivity and oral activity.JTE-907 exhibits anti-inflammatory activity in vivo.
|
| T0851 |
Pregnenolone
|
145-13-1
|
100%
|
|
|
Pregnenolone (Arthenolone) is an endogenous steroid hormone synthesized from cholesterol, used in the treatment of Alzheimer's disease.
|
| T67896 |
CB2R/FAAH modulator-1
|
928892-60-8
|
100%
|
|
|
CB2R/FAAH modulator-1, a cannabinoid type 2 receptor (CB2R) agonist, is also a fatty acid amide hydrolase (FAAH) inhibitor (IC50=4 μM) that reduces the productio...
|
| TN2268 |
Tetrahydromagnolol
|
20601-85-8
|
100%
|
|
|
Tetrahydromagnolol can activate cannabinoid (CB) receptors.
|
| T3530 |
Otenabant
|
686344-29-6
|
100%
|
|
|
Otenabant (CP-945598) has been investigated for the treatment of Obesity.
|
| T8511 |
TM38837
|
1253641-65-4
|
100%
|
|
|
TM38837 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes.
|
| T24771 |
SCH-336
|
447459-51-0
|
95.01%
|
|
|
SCH-336 is a CB2 receptor agonist (Ki-1.8 nM, EC50-2 nM) with effective, selective, and oral activity. SCH-336 is also bioactive against CB1 receptor, and is 100...
|
| TN5131 |
Tetrahydrocannabivarin
|
31262-37-0
|
96.30%
|
|
|
Tetrahydrocannabivarin (CRM) is a neutral cannabis receptor subtype (CB1) receptor antagonist, it can increases neural responding to rewarding and aversive stimu...
|
| T14302 |
Olorinab
|
1268881-20-4
|
97.13%
|
|
|
Olorinab (APD 371) (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB2) agonist. With an EC50 of 6.2 nM for hCB2.
|
| T1915 |
AM251
|
183232-66-8
|
97.88%
|
|
|
AM251 is a effective CB1 receptor antagonist (IC50/Ki: 8 /7.49 nM) that displays 306-fold selectivity over CB2 receptors; also effective GPR55 agonist (EC50: 39 ...
|
| T3S0738 |
Yangonin
|
500-62-9
|
98%
|
|
|
Yangonin (Y100550) is a novel CB receptor ligand, it exhibits affinity for the human recombinant CB receptor. Yangonin (Y100550) could be a valuable candidate fo...
|
| T7375 |
A-836339
|
959746-77-1
|
98%
|
|
|
A-836339 acts as a potent cannabinoid receptor full agonist which has a higher affinity for the peripheral CB2 receptor (Ki = 0.64 nM) over the central CB1 recep...
|
| T3699 |
Bay 59-3074
|
406205-74-1
|
98%
|
|
|
Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM). In rat models of chronic neuropathic and inflammatory pain, it displays anti-hyperalgesic a...
|
| T5996 |
CB1-IN-1
|
1429239-98-4
|
98%
|
|
|
CB1-IN-1 (DBPR211) is a peripherally restricted CB1R antagonist, for CB1R and CB2R with Ki of 0.3 nM and 21 nM,respectively.
|
| T2635 |
Org 27569
|
868273-06-7
|
98%
|
|
|
Org 27569, an allosteric modulator of cannabinoid CB1 receptor, can induce a CB1 receptor state that is characterized by decreased inverse agonist affinity and e...
|
| T1519L |
Rimonabant
|
168273-06-1
|
98%
|
|
|
Rimonabant (SR141716) is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its m...
|
| T22009 |
CB2 receptor agonist 2
|
1314230-75-5
|
98.07%
|
|
|
CB2 receptor agonist 2 (ZINC72105556) is a potent and selective agonist for the CB2 (cannabinoid type 2) receptor, Ki = 8.5 nM. CB2 receptor agonist 2 has high a...
|
